Press Releases
 2010
PRESS RELEASE | 2 September 2010
In his opening address to the 8th EGA International Symposium on Biosimilar Medicines today in London, EGA Director General Greg Perry praised the EU for continuing to inspire the rest of the world regarding the development of scientific biosimilar guidelines. “If healthcare systems are to continue to function long-term”, he said, “we must address the importance of biosimilar monoclonal antibodies next. Science for monoclonal antibodies is already here today and our industry is expecting a workable guideline”. More...
PRESS RELEASE | 8 July 2010
PRESS RELEASE | 1 July 2010
The European Generic medicines Association has welcomed the Decision from the European Court of Justice, which has endorsed the European Commission’s findings that Astra Zeneca abused its dominant position in the market for proton pump inhibitors. The Court confirmed there was clear evidence of anti-competitive activity, through misuse of the patent and regulatory systems, in order to delay the entry of generic Omeprazol, the active ingredient in the company’s blockbuster drug, Losec.
- More information on the AstraZeneca case is available under: http://curia.europa.eu/jcms/upload/docs/application/pdf/2010-07/cp100067en.pdf
- European Commission press release: Antitrust: Commission welcomes Court judgment in AstraZeneca case
More...
PRESS RELEASE | 3 June 2010
“Increasing generic medicines market penetration is the fastest way towards considerable and sustainable savings for healthcare systems in Europe”. This is the key message delivered by EGA President Didier Barret to delegates at the EGA’s Annual General Meeting in Rome on 3 and 4 June 2010. More...
PRESS RELEASE | 1 June 2010
The EGA’s 3rd Bioequivalence Forum is set to focus exclusively on the revised Guideline on the Investigation of Bioequivalence http://www.ema.europa.eu/pdfs/human/qwp/140198enrev1fin.pdf More...
PRESS RELEASE | 6 May 2010
More...
PRESS RELEASE | 27 April 2010
“Today’s vote on falsified medicines has ensured that patient safety will be strongly secured by focusing anti-counterfeiting measures on high priced-high risk products. The European Parliament’s ENVI committee’s decision has also ensured that all safety features designed to secure the legitimate supply chain will be cost-effective, whilst guaranteeing the independence of databases. Moreover the MEPs have correctly focused measures to tackle the sale of counterfeited medicines on the internet where the major problem lies” says Greg Perry, EGA director general, commenting on the ENVI vote. More...
PRESS RELEASE | 25 March 2010
“It is time for European policy makers to take actions to ensure a long term healthy generic business in Europe.” This call was issued in the opening statement of Greg Perry, EGA director general, at the 2nd Sustainability Conference organised by the EGA in Brussels today. More...
PRESS RELEASE | 23 March 2010
The sustainability of the generic medicines sector is vital to ensure accessibility and affordability of modern day pharmaceuticals in global healthcare systems. This is the conclusion drawn in a report from IMS Health published yesterday, and welcomed by the European Generic medicines Association (EGA). More...
PRESS RELEASE | 11 March 2010
"If the patent system is not reformed in Europe, drug manufacturers will encounter increasing hurdles to competition and real innovation." This was the message delivered by Greg Perry, director general of the EGA, in his opening address to delegates at the 6th EGA legal affairs forum on 11 March 2010, in Munich, Germany. More...
PRESS RELEASE | 3 March 2010
“New controls of Active Pharmaceutical Ingredients (APIs) must be workable, effective and ensure continuous supply of all medicines”. This was the key message of Greg Perry director general of the European Generic medicines Association (EGA) at the round table hosted by MEP Judith Merkies and MEP Marisa Matias on “Effective Controls against Falsification in Active Pharmaceutical Ingredients and Excipients” in the European Parliament on 2 March. More...
PRESS RELEASE | 21 January 2010
Greg Perry, director general of the European Generic medicines Association (EGA) opened the 9th edition of the EGA Scientific and Regulatory Affairs Conference in London, by reiterating the association’s vision to create an improved European regulatory framework for generic and biosimilar medicines. More...
PRESS RELEASE | 20 January 2010
During the ongoing codecision procedure, policy makers must keep in mind the objectives of the European Commission pharmacovigilance legislative proposals which consist in strengthening, but also streamlining and rationalising, the Community pharmacovigilance system with a view to preventing unnecessary patient exposure to risks.
This was the key message given by Suzette Kox, EGA Senior Director Scientific Affairs, at the EGA’s 3rd Pharmacovigilance Discussion Forum in London today. A number of national competent authorities and the European Consumers’ Organisation participated in the forum.
More...
|
